Serum fibroblast growth factor 21 levels are increased in atrial fibrillation patients

Cytokine

Volumn 73, Issue 1, 2015, Pages 176-180

  Han, Xinyuan ^a   Chen, Chunyan ^b   Cheng, Gong ^a   Xie, Cui ^a   Yang, Meng ^a   Shou, Xiling ^a   Sun, Chaofeng ^b  

^a SHAANXI PROVINCIAL PEOPLE S HOSPITAL   (China)

^b XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Adipokine; Atrial fibrillation; Fibroblast growth factor 21; Obesity

Indexed keywords

C REACTIVE PROTEIN; FIBROBLAST GROWTH FACTOR 21; FIBROBLAST GROWTH FACTOR;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHINESE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENDER; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; WAIST CIRCUMFERENCE; ATRIAL FIBRILLATION; BLOOD; CASE CONTROL STUDY; MIDDLE AGED;

AGED; ATRIAL FIBRILLATION; CASE-CONTROL STUDIES; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; MALE; MIDDLE AGED;

EID: 84924338616     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2015.02.019     Document Type: Article

References (31)

1. Go A.S., Mozaffarian D., Roger V.L., Benjamin E.J., Berry J.D., Borden W.B., et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013, 127:e6.
2. Benjamin E.J., Levy D., Vaziri S.M., D'Agostino R.B., Belanger A.J., Wolf P.A. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham heart study. JAMA 1994, 271:840-844.
3. Wang T.J., Parise H., Levy D., D'Agostino R.B., Wolf P.A., Vasan R.S., et al. Obesity and the risk of new-onset atrial fibrillation. JAMA 2004, 292:2471-2477.
4. Frost L., Hune L.J., Vestergaard P. Overweight and obesity as risk factors for atrial fibrillation or flutter: the Danish diet, cancer, and health study. Am J Med 2005, 118:489-495.
5. Al Chekakie M.O., Welles C.C., Metoyer R., Ibrahim A., Shapira A.R., Cytron J., et al. Pericardial fat is independently associated with human atrial fibrillation. J Am Coll Cardiol 2010, 56:784-788.
6. Wong C.X., Abed H.S., Molaee P., Nelson A.J., Brooks A.G., Sharma G., et al. Pericardial fat is associated with atrial fibrillation severity and ablation outcome. J Am Coll Cardiol 2011, 57:1745-1751.
7. Thanassoulis G., Massaro J.M., O'Donnell C.J., Hoffmann U., Levy D., Ellinor P.T., et al. Pericardial fat is associated with prevalent atrial fibrillation the Framingham heart study. Circulation: Arrhythmia Electrophysiol 2010, 3:345-350.
8. Kharitonenkov A., Shiyanova T.L., Koester A., Ford A.M., Micanovic R., Galbreath E.J., et al. FGF-21 as a novel metabolic regulator. J Clin Invest 2005, 115:1627-1635.
9. Kharitonenkov A., Wroblewski V.J., Koester A., Chen Y.-F., Clutinger C.K., Tigno X.T., et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 2007, 148:774-781.
10. Dushay J., Chui P.C., Gopalakrishnan G.S., Varela-Rey M., Crawley M., Fisher F.M., et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 2010, 139:456-463.
11. Zhang X., Yeung D.C., Karpisek M., Stejskal D., Zhou Z.-G., Liu F., et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008, 57:1246-1253.
12. Chavez A.O., Molina-Carrion M., Abdul-Ghani M.A., Folli F., DeFronzo R.A., Tripathy D. Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care 2009, 32:1542-1546.
13. Lin Z., Wu Z., Yin X., Liu Y., Yan X., Lin S., et al. Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PloS one 2010, 5:e15534.
14. Chow W.S., Xu A., Woo Y.C., Tso A.W., Cheung S.C., Fong C.H., et al. Serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors. Arterioscler Throm Vas Biol 2013, 33:2454-2459.
15. Semba R., Crasto C., Strait J., Sun K., Schaumberg D., Ferrucci L. Elevated serum fibroblast growth factor 21 is associated with hypertension in community-dwelling adults. J Hum Hypertens 2012, 27:397-399.
16. Lee Y., Lim S., Hong E.S., Kim J.H., Moon M.K., Chun E.J., et al. Serum FGF21 concentration is associated with hypertriglyceridaemia, hyperinsulinaemia and pericardial fat accumulation, independently of obesity, but not with current coronary artery status. Clin Endocrinol (Oxf) 2014, 80:57-64.
17. Fuster VRL, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JLLHJ, et al. American College of Cardiology/, European AHATFoPG, European SoCCfPG, Society. HRAHR. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006;114:e257-e354.
18. Venteclef N., Guglielmi V., Balse E., Gaborit B., Cotillard A., Atassi F., et al. Human epicardial adipose tissue induces fibrosis of the atrial myocardium through the secretion of adipo-fibrokines. Europ Heart J 2013, eht099.
19. Lin Y.K., Chen Y.C., Chen J.H., Chen S.A., Chen Y.J. Adipocytes modulate the electrophysiology of atrial myocytes: implications in obesity-induced atrial fibrillation. Basic Res Cardiol 2012, 107:293.
20. Tyynismaa H., Raivio T., Hakkarainen A., Ortega-Alonso A., Lundbom N., Kaprio J., et al. Liver fat but not other adiposity measures influence circulating FGF21 levels in healthy young adult twins. J Clin Endocrinol Metab 2010, 96:E351-E355.
21. Yan H., Xia M., Chang X., Xu Q., Bian H., Zeng M., et al. Circulating fibroblast growth factor 21 levels are closely associated with hepatic fat content: a cross-sectional study. PloS one 2011, 6:e24895.
22. Mutanen A., Heikkilä P., Lohi J., Raivio T., Jalanko H., Pakarinen M.P. Serum FGF21 increases with hepatic fat accumulation in pediatric onset intestinal failure. J Hepatol 2014, 60:183-190.
23. Li H., Fang Q., Gao F., Fan J., Zhou J., Wang X., et al. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol 2010, 53:934-940.
24. Shen Y., Ma X., Zhou J., Pan X., Hao Y., Zhou M., et al. Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease. Cardiovas Diabetol 2013, 12:124.
25. Planavila A., Redondo I., Hondares E., Vinciguerra M., Munts C., Iglesias R., et al. Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nat Commun 2013, 4.
26. Liu S.Q., Roberts D., Kharitonenkov A., Zhang B., Hanson S.M., Li Y.C., et al. Endocrine protection of ischemic myocardium by FGF21 from the liver and adipose tissue. Sci Rep 2013, 3:2767.
27. Patel V., Adya R., Chen J., Ramanjaneya M., Bari M.F., Bhudia S.K., et al. Novel insights into the cardio-protective effects of FGF21 in lean and obese rat hearts. PloS one 2014, 9:e87102.
28. Dostálová I., Haluzikova D., Haluzik M. Fibroblast growth factor 21: a novel metabolic regulator with potential therapeutic properties in obesity/type 2 diabetes mellitus. Physiol Res 2009, 58:1-7.
29. Pinto A., Tuttolomondo A., Casuccio A., Di Raimondo D., Di Sciacca R., Arnao V., et al. Immuno-inflammatory predictors of stroke at follow-up in patients with chronic non-valvular atrial fibrillation (NVAF). Clin Sci (Lond) 2009, 116:781-789.
30. Marott S.C., Nordestgaard B.G., Zacho J., Friberg J., Jensen G.B., Tybjærg-Hansen A., et al. Does elevated C-reactive protein increase atrial fibrillation risk? A Mendelian randomization of 47,000 individuals from the general population. J Am Coll Cardiol 2010, 56:789-795.
31. Özcan K.S., Güngör B., Altay S., Osmonov D., Ekmekçi A., Özpamuk F., et al. Increased level of resistin predicts development of atrial fibrillation. J Cardiol 2014, 63:308-312.